INS and type 1 diabetes mellitus: Meanwhile, T1D patients receiving insulin therapy may generate antibodies against exogenous insulin or insulin analogs (12), causing dysglycaemia with intractable hypoglycaemia, which is named as exogenous insulin antibody syndrome (EIAS) (13).